Liquidia (NASDAQ:LQDA) Insider Sells $31,356.48 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Sanjeev Khindri sold 1,101 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $31,356.48. Following the completion of the transaction, the insider directly owned 64,846 shares in the company, valued at approximately $1,846,814.08. The trade was a 1.67% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Performance

NASDAQ LQDA traded down $0.86 during trading hours on Tuesday, hitting $26.81. 3,092,611 shares of the company’s stock traded hands, compared to its average volume of 5,078,983. Liquidia Corporation has a 52 week low of $21.94 and a 52 week high of $93.61. The firm has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average price is $63.40 and its two-hundred day moving average price is $61.76.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter in the previous year, the business posted ($0.49) earnings per share. The firm’s revenue was up 1842.1% on a year-over-year basis. Equities research analysts predict that Liquidia Corporation will post 2.05 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on LQDA. Stephens set a $130.00 price objective on Liquidia in a research note on Friday, July 24th. HC Wainwright lowered their target price on Liquidia from $130.00 to $58.00 and set a “buy” rating on the stock in a research report on Friday, October 2nd. Wall Street Zen downgraded Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Royal Bank Of Canada set a $130.00 price target on Liquidia in a report on Friday, July 24th. Finally, Bank of America upped their price target on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $83.69.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LQDA. WINTON GROUP Ltd purchased a new position in Liquidia during the second quarter valued at approximately $335,000. Arizona State Retirement System boosted its position in shares of Liquidia by 5.4% in the second quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after purchasing an additional 900 shares during the period. Nykredit A S purchased a new stake in shares of Liquidia in the second quarter worth $177,000. Corient Private Wealth LP purchased a new stake in shares of Liquidia in the second quarter worth $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Liquidia in the second quarter worth $1,236,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement with United Therapeutics that resolves all six pending lawsuits and allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension (PAH). Eliminating years of patent, antitrust and trade-secret litigation reduces regulatory and commercial uncertainty. Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were $222.7 million, while cash and cash equivalents stood at $396.1 million at September 30. Management said it expects to fund the settlement and planned clinical programs from cash and ongoing sales without additional financing. The company also plans to continue developing YUTREPIA and L606.
• Neutral Sentiment: Multiple executives and insiders—including the CEO, CFO, CAO and general counsel—sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales reduced individual holdings but were not discretionary open-market transactions, making them a limited standalone signal of management confidence. Liquidia insider sale filing
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million: $175 million within 30 business days, $145.4 million in installments during 2027 and $60.3 million related to the antitrust litigation. The outflows could materially reduce its cash cushion and constrain investment, even though management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: The company agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label, limiting the product’s addressable market. Liquidia also ended promotion of Treprostinil Injection, eliminating associated commercial revenue opportunities.
• Negative Sentiment: Recent insider activity remains heavily tilted toward selling—106 sales versus one purchase over six months—and a report highlighted a chairman’s share sale. Separately, a law firm announced an investor investigation related to disclosure of YUTREPIA litigation risks, adding potential reputational and legal uncertainty. Liquidia Negatively Rated Stock Pick of the Week

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).